Hanimi Reddy Bapatu
Hanimi Reddy Bapatu has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Venkata Kanaka Srivani Maddala
Department of Chemistry School of Applied Sciences and Humanities (SASH) VIGNAN'S Foundation for Science Technology & Research (VFSTR) Guntur India
2 shared publications - Venugopalarao Mukkapati
Department of Chemistry School of Applied Sciences and Humanities (SASH) VIGNAN'S Foundation for Science Technology & Research (VFSTR) Guntur India
2 shared publications Akshay Gandigawad
1 shared publication- Arjuna Rao Nekkalapudi
Quality Control Department Ascent Pharmaceuticals Inc Central Islip NY USA
1 shared publication Arvind H. Jadhav
1 shared publicationChob Singh
1 shared publication
Latest Publications
- 18 October 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (10) , e70321
Identification and Structural Elucidation of Potential Degradation Impurities in Testosterone Topical Formulation Using LC–MS, NMR and Evaluation of Genotoxicity by Using Knowledge‐Based (Derek Nexus) and a Statistical Method‐Based (TOPKAT) Silico Tools
While developing a topical gel 1% w/w dosage form, significant unknown impurities were observed above their threshold during shelf‐life determination, with relative retention time (RRT) of 0.66, 0.67, and 0.71 in accelerated stability conditions of 40°C temperature and 75% relative humidity sample. Due to the importance of pharmaceutical quality and purity, impurities during manufacture or storage might cause serious side effects. If an unknown impurity exceeds its threshold limits during product stability testing, its structure must be determined to assess the potential risks. Impurities were separated by gradient HPLC on a Kinetex C18 column with 0.1% formic acid mobile phases, detected at 245 nm. Structural characterization was done using liquid chromatography with mass spectrometry (LC–MS) and 1 H NMR (400 MHz). This study investigated and characterized degradation impurities observed during stability testing of a testosterone topical gel formulation. Three degradation impurities, identified as 6β‐hydroxy‐testosterone, 6β‐hydroperoxy‐testosterone, and 6‐keto‐testosterone impurities with molecular masses of 304.42, 320.20, and 302.41, were isolated and characterized using preparative chromatographic, high‐resolution mass spectrometric, and nuclear magnetic resonance techniques, followed by in silico (Q)SAR assessment of their potential genotoxicity using Deductive Estimate of Risk from Existing Knowledge (Derek) Nexus and Toxicity Prediction using Komputer Assisted Technology (TOPKAT) silico tools‐based knowledge and statistical methods. In silico toxicity evaluation with TOPKAT and Derek Nexus indicated that the testosterone impurities at RRT of 0.66, 0.67, and 0.71 are non‐mutagenic, corroborating their designation as ICH M7 Class 5 impurities.
- 18 October 2026
- Published by Wiley in Separation Science Plus
- Vol. 9 (10) , e70321
Identification and Structural Elucidation of Potential Degradation Impurities in Testosterone Topical Formulation Using LC–MS, NMR and Evaluation of Genotoxicity by Using Knowledge‐Based (Derek Nexus) and a Statistical Method‐Based (TOPKAT) Silico Tools
While developing a topical gel 1% w/w dosage form, significant unknown impurities were observed above their threshold during shelf‐life determination, with relative retention time (RRT) of 0.66, 0.67, and 0.71 in accelerated stability conditions of 40°C temperature and 75% relative humidity sample. Due to the importance of pharmaceutical quality and purity, impurities during manufacture or storage might cause serious side effects. If an unknown impurity exceeds its threshold limits during product stability testing, its structure must be determined to assess the potential risks. Impurities were separated by gradient HPLC on a Kinetex C18 column with 0.1% formic acid mobile phases, detected at 245 nm. Structural characterization was done using liquid chromatography with mass spectrometry (LC–MS) and 1 H NMR (400 MHz). This study investigated and characterized degradation impurities observed during stability testing of a testosterone topical gel formulation. Three degradation impurities, identified as 6β‐hydroxy‐testosterone, 6β‐hydroperoxy‐testosterone, and 6‐keto‐testosterone impurities with molecular masses of 304.42, 320.20, and 302.41, were isolated and characterized using preparative chromatographic, high‐resolution mass spectrometric, and nuclear magnetic resonance techniques, followed by in silico (Q)SAR assessment of their potential genotoxicity using Deductive Estimate of Risk from Existing Knowledge (Derek) Nexus and Toxicity Prediction using Komputer Assisted Technology (TOPKAT) silico tools‐based knowledge and statistical methods. In silico toxicity evaluation with TOPKAT and Derek Nexus indicated that the testosterone impurities at RRT of 0.66, 0.67, and 0.71 are non‐mutagenic, corroborating their designation as ICH M7 Class 5 impurities.
- 23 August 2026
- Published by Elsevier in Journal of Environmental Chemical Engineering
- Vol. 14 (5)
Engineered bimetallic electrode materials for sustainable and selective electroreduction of CO2 into value-added products
- 23 August 2026
- Published by Elsevier in Journal of Environmental Chemical Engineering
- Vol. 14 (5)
Engineered bimetallic electrode materials for sustainable and selective electroreduction of CO2 into value-added products
- 18 April 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (4)
Identification and Structural Elucidation of a Potential Citric Acid and Caprolactam Adduct Impurity in Aminocaproic Acid Injection Using Preparative Chromatography, LC–MS, and NMR
Aminocaproic acid (ACA) is a pharmacological substance possessing antifibrinolytic characteristics that improves hemostasis by diminishing excessive bleeding caused by fibrinolysis. The medication is presently available in tablet, capsule, and oral solution forms. The analysis was carried out on Waters Alliance 2695 HPLC system separation module connected to a 2996 Photodiode Array Detector. The separation was achieved using Eclipse XDB‐C18, 4.6 × 250 mm 2 column, and a 5 µm analytical column. In the course of developing a new injectable dosage form, a substantial unknown impurity was identified above its threshold during the determination of its shelf life, with a retention time of 57.5 min after 6 months under accelerated stability conditions of 40°C temperature and 75% relative humidity. Due to the critical significance of pharmaceutical quality and purity, any impurities identified during manufacturing, storage, or transportation may lead to significant adverse or undesirable effects. Should any unknown impurity surpass its threshold limits during the product's stability testing, it is imperative to elucidate its structure to evaluate the potential concerns it may present. This work seeks to elucidate the methodology for identifying isolating and characterizing the unknown impurity detected during the stability testing of ACA injection. The impurity was isolated using preparative chromatography, and its mass was ascertained using high‐resolution mass spectrometry (HRMS). Nuclear magnetic resonance (NMR) spectroscopy was employed for structural elucidation. The research indicates that impurity is a new adduct formed from citric acid and ACA with a molecular mass of 287.10 with a chemical name of 2‐hydroxy‐2‐(2‐oxo‐2‐(2‐oxoazepan‐1‐yl)ethyl)succinic acid.
- 18 April 2025
- Published by Wiley in Separation Science Plus
- Vol. 8 (4)
Identification and Structural Elucidation of a Potential Citric Acid and Caprolactam Adduct Impurity in Aminocaproic Acid Injection Using Preparative Chromatography, LC–MS, and NMR
Aminocaproic acid (ACA) is a pharmacological substance possessing antifibrinolytic characteristics that improves hemostasis by diminishing excessive bleeding caused by fibrinolysis. The medication is presently available in tablet, capsule, and oral solution forms. The analysis was carried out on Waters Alliance 2695 HPLC system separation module connected to a 2996 Photodiode Array Detector. The separation was achieved using Eclipse XDB‐C18, 4.6 × 250 mm 2 column, and a 5 µm analytical column. In the course of developing a new injectable dosage form, a substantial unknown impurity was identified above its threshold during the determination of its shelf life, with a retention time of 57.5 min after 6 months under accelerated stability conditions of 40°C temperature and 75% relative humidity. Due to the critical significance of pharmaceutical quality and purity, any impurities identified during manufacturing, storage, or transportation may lead to significant adverse or undesirable effects. Should any unknown impurity surpass its threshold limits during the product's stability testing, it is imperative to elucidate its structure to evaluate the potential concerns it may present. This work seeks to elucidate the methodology for identifying isolating and characterizing the unknown impurity detected during the stability testing of ACA injection. The impurity was isolated using preparative chromatography, and its mass was ascertained using high‐resolution mass spectrometry (HRMS). Nuclear magnetic resonance (NMR) spectroscopy was employed for structural elucidation. The research indicates that impurity is a new adduct formed from citric acid and ACA with a molecular mass of 287.10 with a chemical name of 2‐hydroxy‐2‐(2‐oxo‐2‐(2‐oxoazepan‐1‐yl)ethyl)succinic acid.
- 7 September 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (1) , 2-13
Development and Validation of a Method for Trace Level Zinc Quantification in Pharmaceutical Zinc Supplements Using a Carboxyl Functional Group Packed Column and Refractive Index Detector
Background: Zinc helps with cell division, growth, wound healing, and carbohydrate breakdown. Humanbeings have to obtain zinc from food or supplements because our bodies do not produce it naturally. In view of the greater advantages (such as low cost, time of analysis, and stability-indicating) compared to other quantification methods (titration, ion chromatography, Atomic absorption spectroscopy) proposed in the literature, a refractive index detector coupled with HPLC has been used in quantification of zinc. Objective: The goal of this research is to develop and validate a sensitive, low-cost, high-resolution, and stability- indicating method for detecting and quantifying zinc levels in zinc supplement pharmaceutical products (injectables, tablets, and capsules). Methods: A novel isocratic reverse-phase HPLC method with a refractive index detector (with sensitivity 64, detector temperature 35°C, and positive polarity) was developed using a carboxyl functional group packed column and 0.8% (v/v) formic acid as the mobile phase to detect and quantify zinc content. Results: The reported method has a good optimal sensitivity (LOQ: 0.006 mg/mL and LOD: 0.002 mg/mL). The correlation coefficient (r) obtained from the zinc calibration plot was greater than 0.998, indicating that the method was linear and that there was a strong correlation between zinc concentration (0.006 mg/mL to 0.375 mg/mL) and peak response. The accuracy at LOQ level was found to be 95–105% and 97–103% at the remaining levels (50, 100, and 150%). Conclusion: The proposed method was successfully developed and validated as per International council for harmonisation (ICH) guidelines. Therefore, this method can be used for the quantitative testing of zinc in the QC laboratory. Highlights: A novel method was developed for zinc levels determination in pharmaceutical products using HPLC with a refractive index detector. The present approach has a quick run time of 10 min and is inexpensive.
- 7 September 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (1) , 2-13
Development and Validation of a Method for Trace Level Zinc Quantification in Pharmaceutical Zinc Supplements Using a Carboxyl Functional Group Packed Column and Refractive Index Detector
Background: Zinc helps with cell division, growth, wound healing, and carbohydrate breakdown. Humanbeings have to obtain zinc from food or supplements because our bodies do not produce it naturally. In view of the greater advantages (such as low cost, time of analysis, and stability-indicating) compared to other quantification methods (titration, ion chromatography, Atomic absorption spectroscopy) proposed in the literature, a refractive index detector coupled with HPLC has been used in quantification of zinc. Objective: The goal of this research is to develop and validate a sensitive, low-cost, high-resolution, and stability- indicating method for detecting and quantifying zinc levels in zinc supplement pharmaceutical products (injectables, tablets, and capsules). Methods: A novel isocratic reverse-phase HPLC method with a refractive index detector (with sensitivity 64, detector temperature 35°C, and positive polarity) was developed using a carboxyl functional group packed column and 0.8% (v/v) formic acid as the mobile phase to detect and quantify zinc content. Results: The reported method has a good optimal sensitivity (LOQ: 0.006 mg/mL and LOD: 0.002 mg/mL). The correlation coefficient (r) obtained from the zinc calibration plot was greater than 0.998, indicating that the method was linear and that there was a strong correlation between zinc concentration (0.006 mg/mL to 0.375 mg/mL) and peak response. The accuracy at LOQ level was found to be 95–105% and 97–103% at the remaining levels (50, 100, and 150%). Conclusion: The proposed method was successfully developed and validated as per International council for harmonisation (ICH) guidelines. Therefore, this method can be used for the quantitative testing of zinc in the QC laboratory. Highlights: A novel method was developed for zinc levels determination in pharmaceutical products using HPLC with a refractive index detector. The present approach has a quick run time of 10 min and is inexpensive.
- 18 July 2023
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 62 (3) , 222-231
Development of HPLC Method for Ixabepilone (Oncology Drug) in Bulk and Dosage Form: Quantification of Impurities and Forced Degradation Studies
The objective of study is to develop a new stability-indicating HPLC method for quantifying ixabepilone degradation products and known process impurities (EPO-2 and Epothilone B) in bulk and injectable dose forms. A gradient stability-indicating RP-HPLC approach was developed to determine the known impurities of ixabepilone in ixabepilone API and ixabepilone for injection. Ixabepilone was subjected to base, acid, oxidation, photolytic and thermal degradations. The gradient approach was used to optimize the mobile phase-A [pH 4.8 acetate buffer (10 mM) and acetonitrile 90:10 v/v] and mobile phase-B [pH 4.8 acetate buffer (10 mM) and acetonitrile 20:80 v/v] of a USP L1 column. A wavelength of 250 nm was chosen based on known impurities and degradation products response, with a 1.0 mL/min flow rate. In compliance with ICH criteria Q2(R1), the developed technique was validated. The stability-indicating-related impurities technique was proven to be appropriate for estimating degrading impurities and known impurities in ixabepilone API and ixabepilone injection.
- 18 July 2023
- Published by Oxford University Press (OUP) in Journal of Chromatographic Science
- Vol. 62 (3) , 222-231
Development of HPLC Method for Ixabepilone (Oncology Drug) in Bulk and Dosage Form: Quantification of Impurities and Forced Degradation Studies
The objective of study is to develop a new stability-indicating HPLC method for quantifying ixabepilone degradation products and known process impurities (EPO-2 and Epothilone B) in bulk and injectable dose forms. A gradient stability-indicating RP-HPLC approach was developed to determine the known impurities of ixabepilone in ixabepilone API and ixabepilone for injection. Ixabepilone was subjected to base, acid, oxidation, photolytic and thermal degradations. The gradient approach was used to optimize the mobile phase-A [pH 4.8 acetate buffer (10 mM) and acetonitrile 90:10 v/v] and mobile phase-B [pH 4.8 acetate buffer (10 mM) and acetonitrile 20:80 v/v] of a USP L1 column. A wavelength of 250 nm was chosen based on known impurities and degradation products response, with a 1.0 mL/min flow rate. In compliance with ICH criteria Q2(R1), the developed technique was validated. The stability-indicating-related impurities technique was proven to be appropriate for estimating degrading impurities and known impurities in ixabepilone API and ixabepilone injection.